Biomimesys
In silico drug development: a perfect supplement to our in vitro 3D BIOMIMESYS technology
Few weeks ago, the Hong Kong–based company Insilico Medicine announced the beginning of a phase 1 clinical trial concerning a potential therapy for idiopathic pulmonary fibrosis. The event might have gone unnoticed but the way to find this drug was exceptional: it was designed “from scratch” by a combination of Read more…
